Fundraising Fox
Calidi Biotherapeutics
San Diego, US · Founded 2021 · Delaware corporation
Find your way into Calidi Biotherapeutics
Sign up to see every warm intro you have to Calidi Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Calidi Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Calidi is a biotech company developing genetic medicine therapies. The page describes it as a biotech startup working in the genetic medicine field.
Founders & leadership
BM
Boris MinevPresident, Medical & Scientific Affairs; Interim Chief Medical Officer2015–2025He is a physician-scientist with background in immuno-oncology, tumor immunology, and stem cell biology, with experience in translational and clinical development across industry and academic settings.
ST
Stephen ThesingChief Business Officer2019–2024He has held commercial leadership roles across public, venture-backed, and private equity-owned firms in biopharma and healthcare technology.
TK
Tony KalajianInterim Chief Financial Officer
AP
Amish PatelSVP Technical Operations2023–2024He brings expertise in CMC strategy, regulatory affairs across multiple agencies, and leading cross-functional teams across research, development, manufacturing, and quality functions; he has also served as a principal investigator on NIH grants.
AC
Allan CamaisaNamed on SEC filing
HL
Heehyoung LeeNamed on SEC filing
AZ
Alfonso ZuluetaNamed on SEC filing
AF
Anthony F. SantidrianNamed on SEC filing
WP
Wendy PizarroNamed on SEC filing
SL
Scott LeftwichNamed on SEC filing
JA
James A. SchoeneckNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$15.3M disclosed across 7 of 8 rounds · 2023–2026
▶$5.5MraisedJun 2024 · 9 investors · BiotechnologyRule 506(b)
▶$5.5MraisedJun 2024 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James A. SchoeneckDirector
- George NgDirector
- Boris MinevExecutive Officer
- Scott LeftwichDirector
- Wendy PizarroExecutive Officer
- Alan R. StewartDirector
- Andrew JacksonExecutive Officer
- Allan CamaisaExecutive Officer, Director
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- Sales commissions
- $393.2K
- Placement agents
- LADENBURG THALMANN & CO. INC.
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$32.5KraisedMar 2024 · 1 investors · BiotechnologyRule 506(b)
▶$32.5KraisedMar 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan R. StewartDirector
- George NgDirector
- Boris MinevExecutive Officer
- James A. SchoeneckDirector
- Allan CamaisaExecutive Officer, Director
- David LaPreDirector
- Andrew JacksonExecutive Officer
- Wendy PizarroExecutive Officer
- Scott LeftwichDirector
- Offering amount
- $65K
- Amount sold
- $32.5K
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$10KraisedMar 2024 · 1 investors · BiotechnologyRule 506(b)
▶$10KraisedMar 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David LaPreDirector
- Wendy PizarroExecutive Officer
- James A. SchoeneckDirector
- Andrew JacksonExecutive Officer
- Alan R. StewartDirector
- George NgDirector
- Allan CamaisaExecutive Officer, Director
- Scott LeftwichDirector
- Boris MinevExecutive Officer
- Offering amount
- $10K
- Amount sold
- $10K
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$195KraisedMar 2024 · 1 investors · BiotechnologyRule 506(b)
▶$195KraisedMar 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan R. StewartDirector
- Andrew JacksonExecutive Officer
- George NgDirector
- David LaPreDirector
- Boris MinevExecutive Officer
- Allan CamaisaExecutive Officer, Director
- Scott LeftwichDirector
- James A. SchoeneckDirector
- Wendy PizarroExecutive Officer
- Offering amount
- $341.3K
- Amount sold
- $195K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$3.5MraisedMar 2024 · 1 investors · BiotechnologyRule 506(b)
▶$3.5MraisedMar 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott LeftwichDirector
- Andrew JacksonExecutive Officer
- George NgDirector
- Boris MinevExecutive Officer
- Wendy PizarroExecutive Officer
- Alan R. StewartDirector
- David LaPreDirector
- James A. SchoeneckDirector
- Allan CamaisaExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1MraisedMar 2024 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedMar 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wendy PizarroExecutive Officer
- Boris MinevExecutive Officer
- Allan CamaisaExecutive Officer, Director
- Andrew JacksonExecutive Officer
- David LaPreDirector
- George NgDirector
- Scott LeftwichDirector
- James A. SchoeneckDirector
- Alan R. StewartDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$5MraisedJun 2023 · 1 investors · BiotechnologyRule 506(c)
▶$5MraisedJun 2023 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Allan CamaisaExecutive Officer, Director
- Heehyoung LeeDirector
- James SchoeneckDirector
- Alfonso ZuluetaDirector
- Anthony F. SantidrianExecutive Officer
- Boris MinevExecutive Officer
- Stephen ThesingExecutive Officer
- Tony KalajianExecutive Officer
- Amish PatelExecutive Officer
- David SansExecutive Officer
- Wendy PizarroExecutive Officer
- Scott LeftwichDirector
- George NgDirector
- Offering amount
- $25M
- Amount sold
- $5M
- Sales commissions
- $50K
- Proceeds to insiders
- $648K
- Placement agents
- Brookline Capital Markets
- First sale
- Jun 2023
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies working in the same space as Calidi Biotherapeutics.
In the news
Frequently asked questions
- What does Calidi Biotherapeutics do?
- Calidi is a biotech company developing genetic medicine therapies. The page describes it as a biotech startup working in the genetic medicine field.
- How much funding has Calidi Biotherapeutics raised?
- Calidi Biotherapeutics has disclosed $15.3M raised across 7 of its 8 known rounds.
- Where is Calidi Biotherapeutics headquartered?
- Calidi Biotherapeutics is headquartered in San Diego, US.